See more : Taiton Resources Limited (T88.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Reneo Pharmaceuticals, Inc. (RPHM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reneo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chunghwa Precision Test Tech. Co., Ltd. (6510.TWO) Income Statement Analysis – Financial Results
- Yangtze Optical Fibre And Cable Joint Stock Limited Company (601869.SS) Income Statement Analysis – Financial Results
- Mida Assets Public Company Limited (MIDA.BK) Income Statement Analysis – Financial Results
- Nine Entertainment Co. Holdings Limited (NNMTF) Income Statement Analysis – Financial Results
- Birchcliff Energy Ltd. (BIR.TO) Income Statement Analysis – Financial Results
Reneo Pharmaceuticals, Inc. (RPHM)
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 525.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| Gross Profit | -525.00K | -529.00K | -50.00K | -37.00K | -34.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 56.61M | 37.71M | 28.17M | 15.94M | 13.10M |
| General & Administrative | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Selling & Marketing | 26.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.79M | 16.14M | 11.65M | 3.61M | 2.38M |
| Other Expenses | 650.00K | 1.89M | 48.00K | 87.00K | 3.04M |
| Operating Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Cost & Expenses | 83.05M | 53.85M | 39.82M | 19.55M | 15.47M |
| Interest Income | 0.00 | 1.89K | 48.00 | 87.00K | 456.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 170.00K | 529.00K | 50.00K | 37.00K | 34.00K |
| EBITDA | -82.23M | -53.76M | -39.77M | -19.52M | -15.44M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.05M | -53.85M | -39.82M | -19.55M | -15.47M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.67M | 1.89M | 48.00K | 87.00K | 3.04M |
| Income Before Tax | -77.39M | -51.96M | -39.77M | -19.47M | -12.44M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 650.00K | -1.89M | -186.56K | -169.30K | -137.86K |
| Net Income | -77.39M | -50.06M | -39.77M | -19.47M | -12.44M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| EPS Diluted | -25.23 | -2.04 | -2.19 | -0.80 | -1.60 |
| Weighted Avg Shares Out | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
| Weighted Avg Shares Out (Dil) | 3.07M | 24.50M | 18.14M | 24.21M | 7.79M |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM
NEW YORK , May 13, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc....
Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure
MILWAUKEE , May 13, 2024 /PRNewswire/ -- Ademi LLP is investigating Reneo (Nasdaq: RPHM) for possible breaches of fiduciary duty and other violations of law in its going private transaction with OnKure. Click here to learn how to join the https://www.ademilaw.com/case/reneo-pharmaceuticals-inc or call...
RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo shareholders. Pre-merger Reneo shareholders are expected to own approximately 31% of the...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the first quarter...
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter...
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
Topline data results from the pivotal STRIDE study are expected in December 2023 Topline data results from the pivotal STRIDE study are expected in December 2023
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company's management team...
Source: https://incomestatements.info
Category: Stock Reports